Yüklüyor......
Proteasome inhibitors as experimental therapeutics of autoimmune diseases
Current treatment strategies for rheumatoid arthritis (RA) consisting of disease-modifying anti-rheumatic drugs or biological agents are not always effective, hence driving the demand for new experimental therapeutics. The antiproliferative capacity of proteasome inhibitors (PIs) has received consid...
Kaydedildi:
| Yayımlandı: | Arthritis Res Ther |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4308859/ https://ncbi.nlm.nih.gov/pubmed/25889583 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0529-1 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|